Sleep Aids Market by Product and Sleep Disorder - Global Opportunity Analysis and Industry Forecast, 2017-2023

  • ID: 4227018
  • Report
  • Region: Global
  • 120 pages
  • Allied Analytics LLP
1 of 5

FEATURED COMPANIES

  • Cadwell Laboratories Inc.
  • Compumedics Limited
  • DeVilbiss Healthcare LLC.
  • GlaxoSmithKline plc.
  • Koninklijke Philips N.V.
  • Merck & Co.
  • MORE

Sleep Aids Market by Product (Mattress & Pillows, Sleep Laboratories, Medications, and Sleep Apnea Devices) and Sleep Disorder (Insomnia, Sleep Apnea, Restless Leg Syndrome, Narcolepsy, Sleep Walking, and Other Sleep Disorders) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Sleep aids are drugs and devices that are used to diagnose and treat sleep disorders, such as sleep apnea and insomnia. Sleep disorders are caused due to substance misuse, stressful work environment, and inconsistent sleep pattern. Sleep aids help to improve the quality of sleep by reducing the time required to fall asleep and increasing the duration of quality sleep. The global sleep aids market was valued at $49,543 million in 2016, and is estimated to reach $79,851 million by 2022, registering a CAGR of 7.0% from 2017 to 2023.

The global sleep aids market is segmented based on product, sleep disorder, and geography. Based on product, it is categorized into mattress & pillows, sleep laboratories, medications, and sleep apnea devices. The medications segment is further divided into prescription-based drugs, over-the-counter (OTC) drugs, and herbal drugs. Based on sleep disorder, it is classified into insomnia, sleep apnea, restless leg syndrome, narcolepsy, sleep walking, and other sleep disorder. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The market growth is attributed to the surge in prevalence of sleep disorders, rise in geriatric and obese population, and change in lifestyle. The surge in disposable income; increase in awareness about sleep disorders; stressful work issues; enhanced intake of caffeine, tobacco, and alcohol; and technological advancements are expected to boost the sleep aids market growth. However, adverse effects of sleep aids medication in patient with sleep disorders, such as dizziness, diarrhea, constipation, daytime drowsiness; and expiration on sleep drugs patents are expected to hamper the market growth.

KEY MARKET BENEFITS

This report offers a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.
Market estimations provided are based on comprehensive analysis of the key developments in the industry.
The global market is comprehensively analyzed with respect to product, sleep disorder, and geography.
In-depth analysis based on geography facilitates in analyzing the regional market to assist in strategic business planning.
The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.

KEY PLAYERS PROFILED

Koninklijke Philips N.V.
Merck & Co.
Sanofi
DeVilbiss Healthcare LLC.
Pfizer Inc.
SleepMed Inc.
Cadwell Laboratories Inc.
Compumedics Limited
Natus Medical Incorporated
GlaxoSmithKline plc.
Sleep Aids Market Key Segments

BY PRODUCT

Mattresses & Pillows
Sleep Laboratories
Medications
Prescription-based drugs
OTC drugs
Herbal drugs
Sleep Apnea Devices

BY SLEEP DISORDER

Insomnia
Sleep Apnea
Restless Legs Syndrome
Narcolepsy
Sleep Walking
Other Sleep Disorders

BY GEOGRAPHY

North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
Rest of Asia-Pacific
LAMEA
Brazil
Turkey
Republic of South Africa
Saudi Arabia
Rest of LAMEA
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Cadwell Laboratories Inc.
  • Compumedics Limited
  • DeVilbiss Healthcare LLC.
  • GlaxoSmithKline plc.
  • Koninklijke Philips N.V.
  • Merck & Co.
  • MORE
CHAPTER 1. INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2. EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3. MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY BENEFITS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PATENT ANALYSIS

3.3.1. Patent analysis by year
3.3.2. Patent analysis by region
3.3.3. Patent analysis by sleep disorder

3.4. GOVERNMENT REGULATIONS

3.4.1. U.S. FDA
3.4.2. Europe CE Mark
3.4.3. Ministry of Health, Labor, and Welfare (MHLW)

3.5. TOP PLAYERS POSITIONING, 2016
3.6. MARKET DYNAMICS

3.6.1. Drivers

3.6.1.1. Modern lifestyle increases the risk of sleep disorders
3.6.1.2. Stressful Work Condition and Working in Shifts
3.6.1.3. Rise in geriatric and obese population

3.6.2. Restraints

3.6.2.1. Adverse effects of sleep aid medication
3.6.2.2. Patent expiration

3.6.3. Opportunities

3.6.3.1. Technological Advancements Leading to Better Adoption
3.6.3.2. Untapped Markets in Developing Economies

CHAPTER 4. GLOBAL SLEEP AIDS MARKET, BY PRODUCT TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. MATTRESSES AND PILLOWS

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast

4.3. SLEEP LABORATORIES

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast

4.4. MEDICATIONS

4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast
4.4.4. Prescription-based drugs
4.4.5. OTC drugs

4.5. SLEEP APNEA DEVICES

4.5.1. Key market trends
4.5.2. Key growth factors and opportunities
4.5.3. Market size and forecast

CHAPTER 5. SLEEP AIDS MARKET, BY SLEEP DISORDER

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. INSOMNIA

5.2.1. Market size and forecast

5.3. SLEEP APNEA

5.3.1. Market size and forecast

5.4. RESTLESS LEGS SYNDROME

5.4.1. Market size and forecast

5.5. NARCOLEPSY

5.5.1. Market size and forecast

5.6. SLEEPWALKING

5.6.1. Market size and forecast

5.7. OTHERS

5.7.1. Market size and forecast

CHAPTER 6. SLEEP AIDS MARKET, BY GEOGRAPHY

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Rest of Europe market size and forecast

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. Australia market size and forecast
6.4.3.4. India market size and forecast
6.4.3.5. Rest of Asia-Pacific market size and forecast

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. Brazil market size and forecast
6.5.3.2. Turkey market size and forecast
6.5.3.3. Saudi Arabia market size and forecast
6.5.3.4. South Africa market size and forecast
6.5.3.5. Rest of LAMEA market size and forecast

CHAPTER 7. COMPANY PROFILES

7.1. CADWELL INDUSTRIES INC.

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments

7.2. COMPUMEDICS LIMITED

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments

7.3. DRIVE DEVILBISS HEALTHCARE

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments

7.4. GLAXOSMITHKLINE PLC

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments

7.5. MERCK & CO., INC.

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments

7.6. NATUS MEDICAL INCORPORATED

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.6.6. Key strategic moves and developments

7.7. PFIZER INC.

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments

7.8. KONINKLIJKE PHILIPS N.V.

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments

7.9. SANOFI

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Product portfolio
7.9.4. Business performance
7.9.5. Key strategic moves and developments

7.10. SLEEPMED INC.

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Cadwell Laboratories Inc.
  • Compumedics Limited
  • DeVilbiss Healthcare LLC.
  • GlaxoSmithKline plc.
  • Koninklijke Philips N.V.
  • Merck & Co.
  • MORE
According to a new report titled, Sleep Aids Market - Global Opportunity Analysis and Industry Forecast, 2017-2023," the global sleep aids market accounted for $49,543 million in 2016, and is estimated to reach at $79,851 million by 2023, registering a CAGR of 7.0% from 2017 to 2023. North America is the highest contributor in the sleep aids market; however, Asia-Pacific has witnessed the highest growth rate in 2016.

Sleep aids in the form of drugs and medical devices are used for the diagnosis and treatment of sleep disorders, such as sleep apnea and sleep walking. These are expected to improve the quality of sleep for patients with sleep disorders. Sleep disorders could adversely affect the human health and cause chronic diseases, such as diabetes and cardiovascular diseases.

Change in lifestyle, stressful working condition, other issues that interfere with the sleep habits, rise in the disposable income among the customers, and growth in awareness about the adverse effects of sleep disorder on human health are expected to boost the growth of sleep aids market. The risk of sleep disorder increases with age and obesity thus, the rise in the geriatric and obese population could increase the prevalence of sleep disorder, which is expected to fuel the market growth. The rise in demand for sleep aids has also lead to an increase in the advancement of the technology, which will further open new avenues for the market growth. However, the adverse effects of sleep drugs on human health and patent expiration are expected to hamper the market growth.

The mattress & pillows segment was the highest revenue contributor in 2016, and is anticipated to continue this trend during the forecast period. Availability of a variety of products, awareness about the health benefits of quality sleep, and advancement in manufacturing techniques are some of the driving factors for the growth of this segment. Insomnia dominates the sleep aids market and is expected to remain the highest contributor toward the market growth, owing to the presence of a large population base suffering from insomnia.

In 2015, North America accounted for maximum contribution to the total revenue generated, owing to the high prevalence rate of sleep disorders, presence of high disposable income, and high adoption rate of technologically advanced products. However, Asia-Pacific is expected to witness the highest CAGR during the analysis period, attributable to rise in disposable income, increase in government initiatives to modernize healthcare infrastructure, and rise in healthcare expenditure.

Key Findings of the Sleep Aids Market:

The sleep laboratories segment is projected to grow at the highest rate during the analysis period.
The insomnia segment generated the highest revenue, and is expected to continue its dominance in future.
North America dominated global sleep aids market, and is projected to grow at a CAGR of 6.6%.
China is expected to grow at the highest CAGR of 10.8%in the Asia-Pacific.,
The narcolepsy segment is anticipated to grow at the highest at a CAGR of 9.1%.
The key companies profiled in the report include Koninklijke Philips N.V., Merck & Co., Sanofi, DeVilbiss Healthcare LLC., Pfizer Inc., SleepMed Inc., Cadwell Laboratories Inc., Compumedics Limited, Natus Medical Incorporated, and GlaxoSmithKline plc.
Note: Product cover images may vary from those shown
5 of 5
  • Koninklijke Philips N.V.
  • Merck & Co.
  • Sanofi
  • DeVilbiss Healthcare LLC.
  • Pfizer Inc.
  • SleepMed Inc.
  • Cadwell Laboratories Inc.
  • Compumedics Limited
  • Natus Medical Incorporated
  • GlaxoSmithKline plc.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll